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Available online 1 March 2014AbstractIn our previous study, a fibroblast growth factor-2 (FGF-2)eapatite composite layer coated on titanium screws effectively prevented pin tract
infection in rabbits because of enhanced wound healing; however, the FGF-2eapatite composite layers did not completely prevent pin tract
infection. Thus, we recently developed a poly(ε-caprolactone) (PCL) sponge pad embedded with cefazolin sodium (þCEZ), which has a fast-
acting bactericidal effect. The pad is placed on the skin around the screws. The purpose of this study was to determine the anti-infective efficacy
of the þCEZ pad on the pineskin interface of the FGF-2eapatite-coated titanium screws. The þCEZ pads were prepared by mixing PCL and
CEZ in 1,4-dioxane, followed by freeze-drying and compaction. They were analyzed regarding their surface structure, in vitro CEZ release
profile, and bactericidal activity. The FGF-2eapatite-coated screws were implanted percutaneously in bilateral rabbit proximal tibial meta-
physesdwith and without the þCEZ paddfor 4 weeks (n ¼ 20). The þ CEZ pads consisted of a porous matrix of PCL in which CEZ was
embedded. The CEZ-release profile showed an initial burst on Day 1 and a sustained release lasting for 30 days. The þCEZ pad retained its
bactericidal activity against Staphylococcus aureus after preincubation on an agar plate for 7 days. Based on visual inspection, the pin tract
infection rate was successfully reduced from 72.2% to 15.0% with the þCEZ pad ( p < 0.05), which reduced the bacterial count, especially S.
aureus ( p < 0.05). The histological inflammation rate of the soft tissues was also significantly lower with the þCEZ pad than without it
( p < 0.05). The pin tract infection rate was reduced to one-fifth with the þCEZ pad. Using it as described improves infection resistance during
percutaneous implantation.
Copyright 2014, Asia Pacific Knee, Arthroscopy and Sports Medicine Society. Published by Elsevier (Singapore) Pte Ltd. This is an open access
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Titanium screws coated with fibroblast growth factor-2
(FGF-2)eapatite composite layers have greatly improved
resistance against pin tract infection because of enhanced
wound healing during percutaneous implantation.1e3 Pin tract
infection is the most common complication associated with* Corresponding author. Department of Orthopaedic Surgery, Ibaraki Pre-
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http://dx.doi.org/10.1016/j.asmart.2014.01.001external fixation.4e6 When FGF-2eapatite is used, the FGF-2
enhances wound healing by accelerating fibroblast prolifera-
tion and vascularisation,7e9 and the apatite facilitates inte-
gration between the screw and the surrounding tissues. In a
rabbit percutaneous screw implantation model, the titanium
screws coated with FGF-2eapatite reduced by one-half (from
93.8% to 43.8%) the rate of macroscopic pin tract infection,
compared to titanium screws without the FGF-2eapatite.2
In addition, the interfascial soft tissue that is attached to the
FGF-2eapatite composite layer contains a Sharpey’s fibre-like
tissue rich in blood vessels.3 This suggests that the
FGF-2eapatite enhances the formation of Sharpey’s fibre-likePublished by Elsevier (Singapore) Pte Ltd. This is an open access article under the CC
Fig. 1. Macroscopic view of poly(ε-caprolactone) (PCL) sponge foam
55H. Mutsuzaki et al. / Asia-Pacific Journal of Sports Medicine, Arthroscopy, Rehabilitation and Technology 1 (2014) 54e61tissue in the process of wound healing, thereby reducing the
pin tract infection rate.
Despite this success, pin tract infection is not completely
prevented. One possible reason is bacterial invasion via the pin
tract immediately after implantation of the percutaneous
screw. Because wound healing requires time, even in the
presence of FGF-2eapatite, completely preventing bacterial
invasion especially at the early postoperative stage is
important.
Therefore, we developed a sponge-like pad containing
cefazolin sodium as the antibiotic (þCEZ pad) that is placed
on the skin around the screws coated with the FGF-2eapatite.
The þCEZ pad consists of a porous poly(ε-caprolactone)
(PCL) matrix with CEZ embedded in the matrix. Poly(ε-cap-
rolactone) is a biocompatible and resorbable material that has
been explored as a promising drug carrier.10e12 An advantage
of PCL over other resorbable polymers is that it avoids acid-
ification of the surrounding tissue during resorption. Acidifi-
cation of tissue may have a negative impact on FGF-2-
mediated skin tissue regeneration. Cefazolin sodium is a
first-generation cephalosporin antibiotic that is clinically
effective against infections caused by Staphylococcus aureus,
which causes most pin tract infections.1e3 Therefore, we used
CEZ embedded in PCL. The þCEZ pad may have a fast-
acting effect on bacterial elimination around the screws by
releasing CEZ on contact with blood and/or fluid discharge
from the wound. Therefore, the combination of the þCEZ pad
and titanium screws coated with FGF-2eapatite can greatly
reduce the pin tract infection rate through their complementary
effects, compared to the results without the þCEZ pad. The
purpose of this study was to determine the anti-infective ef-
ficacy of the þCEZ pad on the pineskin interface of the FGF-
2eapatite-coated titanium screws.
Materials and methodsPreparation of the padPoly(ε-caprolactone) foam with or without CEZ was pre-
pared by a freeze-drying process (Fig. 1).13 To prepare the
PCL foam for the þCEA pad, 2 g of PCL (MW ¼ 40,000) and
0.2 g of CEZ were added to 60 g of 1,4-dioxane in a glass
bottle and stirred for 90 minutes for complete dissolution of
the PCL. The solution was cooled to 0C with vigorous stir-
ring to make a sherbet-like mixture. The mixture was vigor-
ously stirred for 16 minutes at 0C, and then stirred for 3
minutes at room temperature. The sherbet-like mixture was
frozen at 70C for 1 hour, and then freeze-dried for 48 hours
to remove the 1,4-dioxane from the PCL framework. For the
non-CEZ (CEZ) pad, the PCL foam was similarly prepared,
but without CEZ. All reagents used for preparing the foam
were obtained from the Wako Pure Chemical Industries
(Tokyo, Japan).
The PCL foam was sliced with a razor blade into 2-mm
sections and pressed at 10 MPa to a 1-mm thickness. Circu-
lar or doughnut-shaped þCEZ and CEZ pads were punched
out of the 1-mm PCL foam sections. Circular pads with a 6.35-mm diameter were used for material characterization and for
the in vitro test. The doughnut-shaped pads with outer and
inner diameters of 13.0 mm and 3.0 mm, respectively, were
used for the in vivo test. The amount of CEZ in the 6.35-mm
pads and 13.0-mm pads were 0.9 mg and 3.5 mg, respectively.
embedded with cefazolin sodium (þCEZ).Characterization of padsAfter coating the pads with a thin gold film, the surfaces of
the þCEZ and CEZ pads were analyzed by a scanning
electron microscope (SEM; XL30; FEI, Tokyo, Japan) and by
an energy dispersive electron probe X-ray (EDX) analyzer
(Genesis 2000; EDAX Japan, Tokyo, Japan).In vitro release of CEZA þCEZ pad was immersed in 10 mL of Hanks’ balanced
salt solution (HBSS; SigmaeAldrich, St. Louis, MO, USA),
which was contained in a tightly capped 15-mL conical
tube.14,15 Ninety-six tubes were prepared and allowed to stand
at 37C. After various periods of time, ranging from 2 hours to
32 days, a 4-mL aliquot of the HBSS was collected from the
tubes (n ¼ 6) and analyzed for the amount of CEZ released
from the þCEZ pad. To calculate the amount of released CEZ,
standard solutions were prepared as follows: CEZ solution
(100 mg/mL) in HBSS was incubated at 37C for the same
period as in the CEZ release test. Prior to each measurement,
the incubated standard solution was diluted 2 times, 4 times,
and 10 times with HBSS to use them as CEZ solutions of
50 mg/mL, 25 mg/mL, and 10 mg/mL, respectively. Because
CEZ in aqueous solution has an absorption peak at 290 nm, the
absorption of the collected HBSS was measured at 290 nm
Fig. 2. Postoperative views of screws coated (A) with a fibroblast growth factor 2 (FGF-2)eapatite composite layer without CEZ (CEZ pad) and (B) with CEZ
(þCEZ pad) in the rabbit proximal tibial metaphysis. CEZ ¼ cefazolin sodium.
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Technologies, Tokyo, Japan).In vitro bactericidal activity testThe in vitro bactericidal activity of the þCEZ pads was
assayed by a method similar to the Kirby-Bauer (KB) antibi-
otic test. The CEZ pads were the negative control; the KB
disks (6.35 mm in diameter; CZ30; Becton, Dickinson, Tokyo,
Japan) were the positive control; and þCEZ pads were placed
on uniformly grown Staphylococcus aureus (ATCC: 29213) in
agar plates (Mueller-Hinton) and incubated at 35C for
24 hours (n ¼ 6). The diameters of the inhibition zones were
measured against S. aureus that formed around the pads or the
KB disks. Prior to the bactericidal activity test, the þCEZ pads
were preincubated on a freshly prepared aseptic agar plate at
35C for 0 days, 3 days, 6 days, 7 days, 12 days, and 13 days
to evaluate the sustained bactericidal activity under conditions
similar to those during actual usage of the þCEZ pads on skin
tissue. By following the manufacturer’s instruction for the KB
disk, the bactericidal activity of the þCEZ pad was estimated
by the diameter of the inhibition zone. The bactericidal ac-
tivity against S. aureus was judged clinically effective when
the inhibition zone had a diameter greater than 18 mm.Formation of the FGF-2eapatite composite layer on
titanium screwsTitanium cancellous screws with a 142-nm thick anodic
oxide layer on the surface (#407-030; SYNTHES,West Chester,
PA, USA)dwhich were 4.0-mm in diameter and 30-mm in
lengthdwere coated with a FGF-2eapatite layer.1e3 In brief, a
supersaturated calcium phosphate solution (10 mL) with acalcium/phosphorus (Ca/P) molar ratio of 2.0 was prepared by
mixing five infusion fluids clinically available in Japan at an
optimised mixing ratio, using 8.137 mL of Ringer’s solution
(Otsuka Pharmaceutical, Tokyo, Japan), 36.85 mL of calcium
chloride corrective injection 1 mEq/mL (Otsuka Pharmaceu-
tical), 0.899 mL of Klinisalz (I’rom Pharmaceutical, Tokyo,
Japan), 18.72 mL of dipotassium phosphate corrective injection
1 mEq/mL (Otsuka Pharmaceutical), and 0.909 mL of sodium
bicarbonate substitution fluid for only BIFIL (Ajinomoto
Pharmaceuticals, Tokyo, Japan). The supersaturated calcium
phosphate solution was supplemented with FGF-2 (Fiblast;
Kaken Pharmaceutical, Tokyo, Japan) at a FGF-2 concentration
of 4 mg/mL. Each titanium cancellous screw was immersed in
10 mL of supersaturated calcium phosphate solution supple-
mented with FGF-2 at 37C for 48 hours.In vivo studyThe screws were implanted percutaneously in the medial
proximal tibia of 20 skeletally mature male Japanese white
rabbits weighing approximately 3 kg. The surgical technique
was the same as that reported in our previous studies.1e3 In
brief, each rabbit was administered an intravenous injection of
barbiturate (40 mg/kg body weight). After shaving the legs, 10
mm incision was made in the skin on the medial proximal
tibia, and a 2.5-mm diameter perforation was made in both
tibial metaphyses by individual taps using sterile techniques.
The screws were implanted in the bilateral medial proximal
tibias of 10 rabbits in each group. After the implantation, the
skin was sutured bilaterally to the screw. The group in which
the screws were percutaneously implanted without the þCEZ
pad was designated as the pad () group (n ¼ 20; Fig. 2A),
and the group in which the þCEZ pad was sutured to the skin
Fig. 3. Scanning electron microscopy images of (A) the CEZ pad and (B) the þCEZ pad. Both pads have randomly folded and twisted surfaces with many holes.
A CEZ granule protrudes from the PCL in the þCEZ pad (arrow). CEZ ¼ cefazolin sodium; PCL ¼ poly(ε-caprolactone).
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(n ¼ 20) (Fig. 2B). The four corners of the pads were sutured
to the skin with 4-0 nylon to prevent their coming off. Each
rabbit was postoperatively allowed to behave freely in its own
cage. The pads were removed 1 week after the operations to
avoid late infections. The rabbits did not receive any other
antibiotics or treatment for their wounds and were sacrificed 4
weeks after the implantation.
All animal experiments were performed in accordance with
the guidelines of the ethics committees of the University of
Tsukuba (Ibaraki, Japan) and the National Institute of
Advanced Industrial Science and Technology (Ibaraki, Japan)
and the U.S. National Institutes of Health (Bethesda, MD)
guidelines for the care and use of laboratory animals (NIH
publication no. 85e23, revised 1985).Classification of pin tract infections by visual inspectionFour weeks after the implantation and prior to when the
rabbits were sacrificed, pin tract infections were evaluated by a
modified Checketts classification method.2,16 Grade 0 corre-
sponds to ‘‘no redness’’ (i.e., no redness, discharge, or pin
loosening is present). Grade 1 corresponds to infection only in
the soft tissue, which is characterised by redness and discharge
around the pin but without pin loosening. Grade 2 corresponds
to infection in the soft and hard tissues, which is characterised
by redness and discharge around the pin with pin loosening
because of osteomyelitis. A third-party physicianwhowas blind
to the group identification evaluated the pin tract infections.Histological analysisThe specimens around the screws coated with a FGF-
2eapatite composite layer were fixed in 10% neutral-buffered
formalin for 7 days, decalcified, and embedded in paraffin.
The paraffin-embedded tissues were sliced in 5-mm sections
parallel to the screw hole and stained with hematoxylin
and eosin (H&E). All sections were examined by light mi-
croscopy (BX-51; Olympus Optical, Tokyo, Japan). Pin tractinflammation of the soft tissue was histologically assessed in a
blind manner by a single pathologist who classified it into one
of three grades (i.e., Grade 0, Grade 1, or Grade 2). Grade
0 corresponded to “no inflammation with good wound heal-
ing”; Grade 1 corresponded to “slight inflammation”; and
Grade 2 corresponded to “severe inflammation”.3 Pin tract
inflammation of the hard tissue was also histologically
assessed in a blind manner by a single pathologist who clas-
sified it into one of three grades (i.e., Grade 0, Grade 1, and
Grade 2). Grade 0 corresponded to “no osteomyelitis”; Grade
1 corresponded to “slight osteomyelitis”; and Grade 2 corre-
sponded to “severe osteomyelitis”.Bacteriological analysisBacterial detection was performed by SRL. Inc., Tachi-
kawa, Tokyo, Japan. Exudates around the screws, collected by
cotton swabs, were inoculated on three types of solid agar
broth: sheep blood agar broth (Becton, Dickinson, Sparks,
MD, USA), chocolate agar broth (Becton), and bromothymol
blue lactose agar broth (Becton). The exudates were also
inoculated into Gifu anaerobe-modified (GAM) semisolid agar
broth (Nissui, Tokyo, Japan). The sheep blood agar broth and
chocolate agar broth were aerobically incubated at 35C for
48 hours, whereas the bromothymol blue lactose agar broth
was anaerobically incubated at 35C for 48 hours. The GAM
semisolid agar broth was incubated 35C for 72 hours. When
no bacterial growth was detected visually on the solid agar
broth after the 48-hour incubation period, some of the incu-
bated GAM semisolid agar broth was subcultured again on the
three solid agar broths. Isolated organisms were identified with
the MicroScan WalkAway Plus system (Siemens, Munich,
Germany). We also analyzed the number of bacterial species
detected per screw in each group.Statistical analysesInhibition zones from the in vitro bactericidal activity test
were compared against the criterion for clinical efficacy (i.e.,
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p < 0.05. The pin tract infection data (i.e., visual inspection
and histological analysis) and the detection rate of each
bacterium in the pad () and pad (þ) groups were compared
by the Chi-square test as the independence test at a signifi-
cance level of p < 0.05. The number of bacterial species
detected per screw in the pad () and the pad (þ) groups
were compared by the Student t test at a significance level
p < 0.05.
Results
Fig. 5. The in vitro bactericidal activity against Staphylococcus aureus of the
þCEZ pads, CEZ pads (i.e., negative control), and KB disks (i.e., positive
control). The inhibitory zone diameters for þ CEZ pads were measured afterCharacterization of the pad
the elution of CEZ on agar plates for various periods up to 13 days. The broken
line corresponds to the inhibitory zone diameter of 18 mm, above which in-
dicates clinical efficacy. *p < 0.05, compared against the criterion for clinical
efficacy (i.e., 18 mm). CEZ ¼ cefazolin sodium; KB ¼ KirbyeBauer.The CEZ and þCEZ pads had randomly rough surfaces
with numerous micropores and macropores (Fig. 3A and B).
These micro- and macropores formed as a result of the so-
lidification and evaporation of 1,4-dioxane during the freeze-
drying process. The resulting porous structure created a
sponge-like, flexible quality that made the pads appropriate for
a skin patch. In the SEM image of the þCEZ pad, pillar-like
granules were embedded within the PCL framework, and some
granules protruded from the PCL (Fig. 3B). These granules
were identified as CEZ because nitrogen, sodium, and sul-
phurdall of which are constituents of CEZdwere detected by
EDX (data not shown). Except for the presence of the CEZ
granules, there was no apparent difference in structure be-
tween the CEZ pads and the þCEZ pads.In vitro release of CEZThe release of CEZ from the þCEZ pad was sustained for
at least 30 days (a slow-release stage, followed a rapid-release
stage). The þCEZ pad quickly released CEZ into HBSS
during the first hour (Fig. 4), thereby increasing the CEZ
concentration to more than the clinically effective concentra-
tion (i.e., 5 mg/mL). Within 1 day, the CEZ concentration had
reached 18 mg/mL. During the following days, immersionFig. 4. The in vitro release profile of CEZ. Concentrations of total CEZ
released from the þCEZ pad after incubation in 10 mL of Hank’s balance salt
solution (HBSS) at 37C for various periods up to 32 days (n ¼ 6). Results are
expressed as the average  the SD. CEZ ¼ cefazolin sodium; SD ¼ standard
deviation.resulted in continued CEZ release, and the CEZ concentration
increased gradually up to 29.4 mg/mL (Fig. 4).In vitro bactericidal activity testThe þCEZ pad demonstrated sustained in vitro bactericidal
activity against S. aureus (Fig. 5). An inhibitory zone diameter
greater than 18 mm against S. aureus indicated that the strain
is sensitive to CEZ and that the þCEZ pad has clinical effi-
cacy for that strain. In this study, the inhibitory zone diameter
of the þCEZ pads against S. aureus was statistically greater
than 18 mm up to 7 days of CEZ elution on the agar plate (Day
0, p < 0.001; Day 3, p < 0.001; Day 6, p ¼ 0.003; and Day 7,
p < 0.001). The CEZ pads (i.e., negative control) had no
inhibitory zone, whereas the KB disks (i.e., positive control)
had a 28.7-mm inhibitory zone diameter (which was signifi-
cantly greater than 18 mm).Classification of pin tract infections by visual inspectionOne rabbit in the pad () group died prior to when it could
be sacrificed. Therefore, the number of specimens were 18
rabbits in the pad () group and 20 rabbits in the pad (þ)
group. A Grade 1 infection (i.e., soft tissue infection) was
observed in both groups. There was no Grade 2 infection (i.e.,
osteomyelitis) in either group. The infection rate (corre-
sponding to the Grade 1 infection rate) was significantly lower
in the pad (þ) group (15.0%) than in the pad () group
(72.2%; p ¼ 0.0004).Histological analysisIn the pad (þ) group, the percentages of Grade 0, Grade 1,
and Grade 2 histological inflammation of the soft tissues were
30.0%, 55.0%, and 15.0%, respectively. However, in the pad
() group, the percentages of Grade 0, Grade 1, and Grade 2
inflammation of the soft tissues were 22.2%, 38.9%, and
38.9%, respectively. The histological inflammation rate of the
soft tissues was significantly lower in the pad (þ) group than
Fig. 6. Histological sections of specimens with (A) Grade 0 infection and (B) Grade 1 infection at 4 weeks after implantation [hematoxylin and eosin stain]. (A) No
inflammation or very mild inflammation of the soft tissues is present around the screws in Grade 0 infection. (B) Soft tissue inflammation is present around the
screws in Grade 1 infection.
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percentages of Grade 0, Grade 1, and Grade 2 histological
osteomyelitis of the hard tissues were 85.0%, 15.0%, and 0%,
respectively. However, in the pad () group, the percentages
of Grade 0, Grade 1, and Grade 2 osteomyelitis of the hard
tissues were 72.2%, 27.8%, and 0%, respectively. There was
no statistically significant difference between the two groups
( p ¼ 0.335). No inflammation or only very mild inflammation
of scar tissue was observed in the soft tissues around the
screws in rabbits with Grade 0 infection (Fig. 6A). By
contrast, necrotic tissue associated with mild or severe
inflammation was observed in the soft tissues around the
screws in rabbits with Grade 1 infection (Fig. 6B).10
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Fig. 7. The bacterial detection rates in the pad () and pad (þ) groups
(n ¼ 18e20). The þ CEZ pad shows a reduced number of Staphylococcus
aureus. The rate of no bacterial detection is 3.3 times higher in the pad (þ)
group than in the pad () group, and the difference is statistically significant.
CEZ ¼ cefazolin sodium.Bacteriological examinationTheþCEZpad reduced the detection rate of S. aureus (Fig. 7).
The rate of S. aureus detection was three times lower in the pad
(þ) group than in the pad () group, and the difference was
statistically significant ( p ¼ 0.021). By contrast, the rate of no
bacterial detectionwas 3.3 times higher in the pad (þ) group than
in the pad () group. The difference was statistically significant
( p ¼ 0.031). The differences in the detection rate of other bac-
teria were not significant between the pad (þ) and pad ()
groups. The number of bacterial species detected per screw was
significantly smaller in the pad (þ) group (0.6 0.7) than in the
pad () group (1.1  0.8; p ¼ 0.018).
Discussion
The infection rate during percutaneous implantation using
screws coated with a FGF-2eapatite composite layer was
reduced to approximately one-fifth when using the þCEZ pad,
based on visual inspection. The histological inflammation rate
of the soft tissues was also significantly lower with the þCEZ
pad than without the pad. According to our previous results on
uncoated titanium screws, most pin tract infections occurred
within 12 days and one-third of them occurred within 4 days.3
Once a pin tract infection occurred prior to wound closure
around the pin, the infection remained for the entire period of
external fixation. Thus, preventing an infection during the
early postoperative period is important for preventing pin tract
infection altogether. This study confirmed that the bactericidal
activity of the þCEZ pad starts immediately and is sustained
for as long as 7 days under conditions similar to placing the
pad on skin tissue (Fig. 5). This result suggests that the þCEZ
pad retains its bactericidal efficacy during the early post-
operative period, when the risk of pin tract infection is
increased. The bactericidal efficacy of the þCEZ pad during
the early postoperative period reduces the infection rate during
external fixation by screws coated with FGF-2eapatite.
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þCEZ pad results from the two-stage release of CEZ from the
þCEZ pad on contact with a liquid medium. The two-stage
release consists of an initial burst during the first day, fol-
lowed by sustained release of CEZ lasting a few weeks
(Fig. 4). The initial release of CEZ from the þCEZ pad is
attributed to the rapid dissolution of CEZ on the PCL surface
(Fig. 3B) because CEZ is highly soluble in an aqueous me-
dium. The later stage of slow release is attributable to the
hydrolytic degradation of the PCL matrix and the resultant
exposure and dissolution of CEZ embedded in the matrix. The
two-stage release of CEZ from the þCEZ pad is likely
induced, even on skin tissue around the screw, by bleeding and
fluid discharge from the wound.
Our previous study showed that titanium screws coated
with FGF-2eapatite reduced pin tract infection by promoting
wound healing.2,3 Wound healing requires time, even with the
aid of FGF-2eapatite. This composite layer, however, has no
direct bactericidal activity to prevent early postoperative
bacterial invasion. The þCEZ pad developed in this study
complements FGF-2eapatite by the initial burst release of
CEZ, followed by a sustained release. Thus, using the þCEZ
pad in combination with the screws coated with a FGF-
2eapatite composite layer effectively improved infection
resistance around the pin tract.
The present screws were prepared under the same condi-
tions as that of previous titanium screws coated with the FGF-
2eapatite layer2; however, the present infection rate for the
pad () group (72.2%) was higher than the rate of the previous
results (43.8%). The increased infection rate is tentatively
ascribed to enforced changes in the animal experimental fa-
cility, which included changes in the operating room, cages of
rabbits, and breeding environment. These changes eventually
can influence the bacterial density in the atmosphere.
Various methods have been attempted to prevent pin tract
infections. The standard approach employed clinically is the
oral or parenteral administration of antibiotics. However, the
continuous use of a large amount of antibiotics has the sec-
ondary risk of antibiotic-resistant bacteria. Alternative
methods using silver, titanium-copper, iodine, chlorhexidine,
and a tobramycin-impregnated polymethylmethacrylate pin
sleeve have recently been reported.17e21 Our method using the
þCEZ pad has the advantages of reducing the amount of an-
tibiotics, simple methodology, and safety. The amount of CEZ
applied by the þCEZ pad was a 7-day total of 0.8 mg/kg,
which was two orders of magnitude smaller than the amount
systemically applied by conventional drip infusion
(20e100 mg/kg per day).22,23 The efficacy of the þCEZ pad
was moreover retained for as long as 7 days under the con-
ditions of use. The þCEZ pad can be easily used indepen-
dently of the screws. Therefore, the þCEZ pad can easily be
positioned, removed, and changed, depending on the symp-
tomatic state of the wound during the implantation. For
example, it can be used when pin tract infection is diagnosed
during external fixation early postoperatively and long-term
after an operation.Reducing the incidence of pin tract infections is clinically
important during the course of treatment by percutaneous
implants such as external fixation. The þ CEZ pad developed
in this study may also decrease the risk of inadequate healing
of a fractured bone, including nonunion.
A limitation of this study is that the data for long-term
implantation and implantation under loaded conditions
remain unclear. Further studies entailing long-term implanta-
tion and implantation under loaded conditions are required. It
is notable that a pad containing other antibiotics can be created
for any bacteria.
In conclusion, a þCEZ pad was prepared by a freeze-
drying process. Antibiotic activity of the þCEZ pad was
detected, even after 7 days of preincubation on an agar plate.
The infection rate was reduced to approximately one-fifth
when using the þCEZ pad. Use of the þCEZ pad thus
effectively improves resistance to infection during percuta-
neous implantation.
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